New Ray Medicine International Holding Limited (HKG:6108)

Market Cap	40.52M -32.7%
Revenue (ttm)	130.37M +38.8%
Net Income	-20.07M
EPS	-0.12
Shares Out	200.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,000
Open	0.2020
Previous Close	0.2020
Day's Range	0.2020 - 0.2020
52-Week Range	0.1910 - 0.4900
Beta	-3.93
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. Its pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepa...

• Industry: Pharmaceutical Retailers
• Sector: Healthcare
• Founded: 2001
• Employees: 31
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6108

Financial Performance

In 2025, HKG:6108's revenue was 130.37 million, an increase of 38.78% compared to the previous year's 93.95 million. Losses were -20.07 million, -35.29% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error